49 results about "Mapk signaling pathway" patented technology

The invention discloses a purpose of a polyether compound in medicine preparation and an anti-tumor medicine screening method. The medicine is used for regulating and controlling at least one of the following signal channels: a calcium ion signal channel, a Wnt signal channel, a Hippo signal channel, a TNF signal channel, a VEGF signal channel, a p53 signal channel, an NF-kappa B signal channel, an Ras signal channel, an mTOR signal channel, an RNA degradation signal channel, a PPAR signal channel, a cAMP signal channel, an HIF-1 signal channel, an Insulin signal channel, an AMPK signal channel, an Rap1 signal channel, an apoptosis signal channel, a cell cycle signal channel, a cGMP-PKG signal channel, a DNA copying signal channel, an MAPK signal channel, a PI3K-Akt signal channel and an autophagy signal channel. The polyether compound provided by the invention can cause the tumor cell death through regulating and controlling various signal channels; and a better anti-cancer effect isachieved.

The invention relates to use of ursolic acid as a colon tumor resistant medicament. The ursolic acid has the effects of inhibiting colon cancer / tumor cell proliferation and inducing apoptosis. In naked mouse in vivo experiments, the ursolic acid can effectively inhibit the proliferation of colon cancer transplanted tumor and inhibit the generation of tumor blood vessels, and has no obvious toxic or side effect on mice. The ursolic acid has the effect of inhibiting EGFR / MAPK signal channel phosphorylation of colon cancer cells, and the key target of the ursolic acid is to inhibit ERK1 / 2 protein phosphorylation. The ursolic acid which is synergetic with oxaliplatin serving as a clinical first-line chemotherapy medicament of the colon cancer has better curative effect. The ursolic acid has better proliferation inhibiting effect on the colon cancer cells of K-RAS gene mutation. The use of the ursolic acid as the colon tumor resistant medicament provides a new thought for treating the colon tumor.

The invention belongs to the technical field of functional analysis methods of disease metabolism biomarkers, and provides a biomarker metabolic pathway and an analysis method. The metabolic biomarker is stearic acid, phytosphingosine, glycine, glutamine and phospholipids; an acting target spot of the metabolic biomarker is a target protein related to a depression nervous system, immune response and endocrine; and the metabolic pathway is a PI3K-Akt signaling pathway, an mTOR signaling pathway, an MAPK signaling pathway, an erbB signaling pathway, a neurenergen signaling pathway, an Rap1 signaling pathway and an Ras signaling pathway. A functional network analysis method suitable for depression characteristics is established, and the clinical application of these biomarkers helps to optimize the diagnosis of depression, and can provide some valuable clues for the subsequent depression network function researches.

The invention belongs to the technical field of medicines and in particular discloses application of strictosamide to preparation of anti-inflammatory drugs. The strictosamide is extracted and separated from nauclea officinalis medicinal materials. The strictosamide can achieve the effects of obviously inhibiting growth of inflammatory factors IL-1beta and TNF-alpha in LPS-stimulated RAW 264.7 cells and inhibiting expression of IL-1beta and TNF-alpha mRNA. Researches of anti-inflammatory mechanisms prove that the strictosamide can inhibit LPS-stimulated NF-kappaB and MAPK signal paths in RAW 264.7 cells.

The invention belongs to the field of biological medicines, and particularly relates to application of NOD1 to preparation of products for inhibiting MAPK signal path. The products have the at least one of the following functions from A1) to A7): A1) combination with SRC; A2) inhibition of expression of p-SRC; A3) inhibition of MAPK signal path; A4) inhibition of expression of p-ERK; A5) inhibition of expression of p-CyclinD; A6) inhibition of expression of p-CyclinE; and A7) promotion of expression of p21. The invention firstly discovers NOD1 can inhibit p-SRC through target binding of SRC and further inhibit the MAPK signal path. The discovery provides a new target spot for screening drugs for treating diseases related to abnormal MAPK signal path.

The invention provides an application of a soybean peptide in promoting osteogenic activity, which comprises the following steps: detecting the proliferation level of osteoblasts, the activity of a marker ALP in the early stage of differentiation and a marker OCN in the later stage of differentiation, and detecting that the soybean peptide CBP promotes the proliferation and differentiation of the osteoblasts on the biochemical level; in the process of promoting osteoblast differentiation by the soybean peptide CBP, three classical signal pathways, namely ERK, JNK and p38 bypasses, of an MAPK signal pathway participate in the process and a key signal transduction step; the soybean peptide CBP promotes gene expression and phosphorylation level of a key factor Runx2 of an MAPK signal channel in osteoblasts.

The invention discloses the use of hordenine in the preparation of drugs for treating pituitary tumors, and relates to the technical field of biopharmaceuticals. Specifically, in this application, the inventors have discovered that hordenine can inhibit TLR4 / NF-κB / The MAPK signaling pathway helps to treat prolactinoma and adrenocorticotropic adenoma to play a drug effect, and solves the plight of drug shortage for patients with prolactinoma and adrenocorticotropic adenoma.

This invention provides compounds of the formula (I):wherein Y1, Y2, Z, X1, X2, and W′ are defined in the specification. These compounds are useful in the treatment of tyrosine kinases, MAPK signaling pathway kinases and PI3K / AKT / mTor signaling pathway kinases-mediated diseases or conditions, such as neurodegeneration, neuroprotection, cancer, autoimmune as well as other diseases and conditions associated with the modulation of tyrosine kinases selected from FYN, FYN Y531F, FLT3, FLT3-ITD, BRK, ITK, FRK, BTK, BMX, SRC, FGR, YES1, LCK, HCK, RET, CSK, LYN, and ROS1; MAPK pathway kinases selected from ARAF, BRAF, CRAF, ERK1 / 2, MEK1, MEK2, MEK3, MEK4, MEK5, MEK6, and MEK7; and PI3K / AKT / mTor pathway kinases: selected from mTor, PI3K α, PI3K β, PI3K γ, and PI3K δ.

The invention discloses the application of amygdalin in the preparation of anti-inflammatory drugs for knee osteoarthritis. In an inflammatory state, AMD regulates the expression of Dnmt3b by inhibiting the p38 / MAPK signaling pathway, thereby delaying the degeneration of chondrocytes. It was verified in vivo that AMD regulates the metabolism of chondrocytes by regulating the p38 / MAPK / Dnmt3b signaling pathway, thereby delaying the degeneration of OA. Therefore, AMD has a good application prospect in the clinical treatment of osteoarthritis. Because the existing anti-inflammatory and analgesic drugs often have gastrointestinal tract reactions, allergic reactions and kidney damage, the present invention can well control side effects within the range of effective doses without affecting the enhancement of the anti-inflammatory ability of chondrocytes.

The invention discloses application of Chinese softshell turtle Cathelicidin-Ps-CATH4 peptide in preparation of an anti-inflammatory drug, and belongs to the technical field of biomedicine. Ps-CATH4 is linear peptide, and contains 32 amino acid residues; RT-PCR displays that the peptide has an inhibition effect on expression of critical inflammatory factors induced by lipopolysaccharide and an inducible NO synthase gene; and on the protein level, the peptide has a negative regulation effect on LPS-induced inflammatory factors and NO release, has an ascending effect on expression of inflammatory factors, and is mainly used for inhibiting release of the inflammatory factors by inhibiting activation of a TLR4 acceptor and a downstream MAPK signal channel. The peptide is simple in structure, does not contain a disulfide bond or a cyclic structure; chemical synthesis and genetic engineering preparation are facilitated; the primary medicinal evaluation shows low cytotoxicity and hemolytic activity; and the peptide is good in stability on salt, blood serum, temperature and time, and is applied to preparation of the anti-inflammatory drug.

The invention discloses application of amygdalin in preparing a knee osteoarthritis anti-inflammatory drug. At an inflammatory state, AMD controls the expression of Dnmt3b by inhibiting a p38 / MAPK signal channel so as to retard the regression of cartilage cells. The AMD adjusts the metabolism of the cartilage cells by controlling the p38 / MAPK / Dnmt3b signal channel, so that the regression of OA isretarded. Therefore, AMD has good application prospect in clinically treating osteoarthritis. The existing anti-inflammatory pain alleviating drug generally has gastrointestinal reaction, anaphylacticreaction, renal damage and the like, the amygdalin can well control the side effect in an effective dose range and does not influence the improvement of the anti-inflammatory capability of cartilagecells.

The invention provides application of polyguluronate sulfate to anti-hepatitis B virus medicine preparation. Experiments prove that the polyguluronate sulfate is capable of well inhibiting expression of an HBV (hepatitis B virus) HBsAg (hepatitis B surface antigen) and an HBV HBeAg (hepatitis Be antigen) in a hepatocellular carcinoma cell line HepG2.2.15, remarkably inhibiting expression of HBV-S mRNA (messenger ribonucleic acid) in the hepatocellular carcinoma cell line HepG2.2.15, enhancing generation and secretion of anti-virus immunity-associated IFN (interferon)-beta in cells and activating NF (nuclear factor)-kappa B and MAPK (mitogen-activated protein kinase) signal pathways. The polyguluronate sulfate which is a marine sulfated polysaccharide compound has the advantages of rich resources, low cost, high safety and the like, and is obviously superior to positive control drug lamivudine in anti-HBV effect, thereby being promising in application prospect of anti-hepatitis B virus medicine preparation.

The invention relates to the application of RPS9 protein in the prediction of good response to superovulation in cynomolgus monkeys, belonging to the technical field of superovulation. The method of proteomics is used to analyze the first day of superovulation success group and the fifth day of superovulation success group. , Superovulation failure group on day 1 and superovulation failure group on day 5 for bioinformatics analysis to obtain the differential protein among the groups. From the study of protein level, the changes of protein expression revealed in the blood of superovulated monkeys were explored. In superovulation in cynomolgus monkeys, RPS9 protein was expressed on day 5 in the superovulation success group, but not in the superovulation failure group on day 5. It is suggested that the down-regulation of PRS9 expression in the superovulation failure group affects the activation of MAPK signaling pathway and NK-κB pathway, thereby leading to cell apoptosis, cell cycle arrest and inhibition of proliferation. The down-regulation of PRS9 expression may lead to the activation of p53, resulting in the inhibition of cell proliferation, thereby affecting the formation of follicles and leading to the failure of superovulation response. Therefore, RPS9 protein has become a new molecule to predict the good response to superovulation in cynomolgus monkeys, and has practical application value.

An application of eriocalyxin B in preparing the medicines for treating acute leukemia and Burkitt's lymphoma is disclosed.